TIBER CREEK GROUP for BRISTOL MYERS SQUIBB
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Issues related to drug pricing and reimbursement for prescription drugs related to H.R. 5376 - Build Back Better Act, Subtitle J (Part B and D drug pricing); H.R.5376 - Inflation Reduction Act of 2022 - Public Law No: 117-169; Issues related to Prescription Drug User Fee Reauthorization; H.R. 6833 Affordable Insulin Now Act (Continuing Resolution Shell); H.R. 7667 - Food and Drug Amendments of 2022; S. 4348 - FDA Safety and Landmark Advancements (FDASLA) Act.
| Lobbyist | Covered position, as disclosed |
|---|---|
| BRYANT HALL | — |
| COREY MALMGREN | — |
Medicare/Medicaid MMM
Issues related to drug pricing and reimbursement for prescription drugs related to H.R. 5376 - Build Back Better Act, Subtitle J (Part B and D drug pricing). H.R.5376 - Inflation Reduction Act of 2022 - Public Law No: 117-169.
| Lobbyist | Covered position, as disclosed |
|---|---|
| BRYANT HALL | — |
| COREY MALMGREN | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.